Cytori to Present at Regen Med Investor Day 2013 on April 17

Before you go, we thought you'd like these...
Before you go close icon

Cytori to Present at Regen Med Investor Day 2013 on April 17

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NAS: CYTX) announced today that President Marc Hedrick, MD will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.


In addition to the corporate presentation, Dr. Hedrick will participate on the "Clinical Outlooks in Cardiovascular Disease" panel, alongside Ronnda Bartel, PhD of Aastrom Biosciences, Silviu Itescu, MBBS of Mesoblast Limited, Linda Marban, PhD of Capricor and Leslie Miller, MD of the University of South Florida Heart Institute.

Specific details for both events are as follows:

        Event:   Clinical Outlooks in Cardiovascular Disease Panel   Cytori Therapeutics Presentation
 
Time:9:00 AM EST1:00 PM EST
 

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features 16 of the regenerative medicine field's leading small- and mid-cap companies. In addition, there will be disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas, President of Shire Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.

A live video webcast of the panels and company presentations will be available at: http://alliancerm.org/rmdaywebcast and will also be published on ARM's website shortly after the event.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com



Cytori Therapeutics
Megan McCormick
mmccormick@cytori.com
+1.858.875.5279

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:

The article Cytori to Present at Regen Med Investor Day 2013 on April 17 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners